A positive anti-CCP test: what it means and what comes next

A positive anti-CCP test raises suspicion for rheumatoid arthritis, especially when joints stay swollen and mornings begin with stiffness. It cannot establish the diagnosis on its own. People without current joint inflammation can also test positive. The next step is to put the result in context with a clinician, rather than assume it predicts a particular future.

What a positive anti-CCP test means

The test detects antibodies against cyclic citrullinated peptides. These belong to a broader group called ACPA, or anti-citrullinated protein antibodies. Citrullination is a chemical change in proteins: enzymes in the PAD family convert the amino acid arginine into citrulline within a protein.

That change is not inherently abnormal. Under certain conditions, however, the immune system recognizes altered structures and makes antibodies against them. This autoimmune response is common in rheumatoid arthritis, or RA. Its development is complex and does not necessarily begin in a joint that is already inflamed. Researchers are also investigating mucosal surfaces, such as those in the lungs and mouth, as possible starting points.

Results are often reported in units or U/mL. Some widely used assays use a threshold around 20 units for a positive result; others have different cutoffs. For example, Mayo Clinic Laboratories lists 20.0–39.9 U as weakly positive for its assay. Always use the range and units supplied by your laboratory. Values from different assays are not automatically interchangeable.

Anti-CCP is relatively specific for RA, but it is not detectable in everyone with the disease. A diagnostic meta-analysis reported pooled sensitivity of 61.7% and specificity of 97.1%. That means the test identified about 62% of RA cases in the included studies and was negative in about 97% of comparison participants without RA. Performance varies by assay and population. Crucially, 97.1% specificity does not mean that every person with a positive result has a 97.1% chance of having RA. That probability also depends on symptoms and how likely RA was before testing.

How a positive result is interpreted

The clinical picture comes first. Persistent swelling, pain, and morning stiffness, particularly in several small joints, make inflammatory arthritis more likely. An examination needs to establish whether the joint lining is inflamed, a finding called synovitis, or whether another cause better explains the symptoms.

Anti-CCP can appear before symptoms. Researchers have observed this in repeated blood-donation samples collected before RA developed. A positive result without symptoms can therefore indicate an at-risk phase, but it does not mean RA is already established or will inevitably develop. Nor can a blood test guarantee that there are no structural changes at that point. Research on autoantibodies before symptom onset documents this timeline.

Higher antibody levels can be relevant to risk and prognosis. They are not a direct measurement of current inflammatory activity, though. Someone doing well on effective treatment may still have high anti-CCP levels. The number should not be read as a day-to-day disease activity gauge.

Rheumatoid factor, or RF, provides additional information. A negative RF result does not cancel out a positive anti-CCP test, and neither marker alone determines the eventual course. A study in early RA specifically examined whether antibody and genetic subgroups differed in their response to initial treatments. It found no evidence that relative treatment effects differed across those subgroups at 48 weeks. It should not be interpreted as proof that double positivity predicts a particular treatment response for an individual.

Age and sex affect the likelihood of RA before testing. Women develop it more often than men, with frequencies roughly two to three times higher in some populations. Men and people outside the typical middle-age range can develop RA too. Symptoms and examination matter more than a rigid demographic rule.

Factors that may be associated with anti-CCP

Certain HLA-DRB1 variants, including the so-called shared epitope, are associated with ACPA-positive RA. This is a genetic predisposition, not a predetermined outcome. Interactions with other factors help explain why many people with these variants never develop the disease. Research on genetic associations explores these relationships.

Smoking is an important risk factor that can be changed. One proposed mechanism involves increased citrullination and immune responses at mucosal surfaces. Quitting does not immediately return risk to that of someone who has never smoked, but risk can decrease over time. The Nurses’ Health Studies analysis examined this association in women; it was observational rather than a randomized trial of quitting.

Researchers are also studying periodontitis and the bacterium Porphyromonas gingivalis. The bacterium can carry out its own citrullination, providing a plausible connection to autoimmune responses. This does not mean that every case of gum disease causes RA or that dental treatment reliably eliminates anti-CCP. Taking care of your mouth remains worthwhile for its own reasons. A research review discusses the possible connection.

Hormones and stress regulation are other areas of research. RA activity can change during pregnancy even when anti-CCP remains relatively stable. Observations linking age at menopause with RA, and studies of neuroendocrine mechanisms, raise useful questions. They do not provide a simple explanation for one person’s high antibody result. Relevant work addresses pregnancy, menopause timing, and stress regulation.

Other findings that help complete the picture

C-reactive protein, or CRP, and the erythrocyte sedimentation rate, or ESR, reflect inflammation but are not specific to RA. Elevated results alongside compatible joint findings support suspicion of active inflammatory disease. Normal levels do not reliably exclude active RA, nor do they prove that a person is only in a preclinical phase.

A complete blood count can reveal anemia or other accompanying findings. Complement levels, such as C3 and C4, may be relevant when considering particular alternative diagnoses or complications. They are not automatically needed to assess every positive anti-CCP result. Rheumatoid vasculitis is a rare, serious complication; several positive immune markers alone do not diagnose it. A review of rheumatoid vasculitis explains the distinction.

Vitamin D is also being studied because of its roles in immune function. Low levels and RA occur together in observational studies. Whether correcting a low level changes the autoimmune disease itself is a separate question. Appropriately treating a confirmed deficiency may benefit general and bone health. It does not promise to lower anti-CCP or prevent RA. A review of vitamin D and RA examines the evidence.

Imaging can provide another view of inflammatory changes. Ultrasound can assess the joint lining and blood flow; MRI may identify certain early changes that are not yet visible on an X-ray. The appropriate test depends on symptoms and examination findings. A positive anti-CCP result without symptoms does not automatically require every type of imaging. EULAR imaging recommendations describe how these methods can be used.

Planning the next step

New or persistently swollen joints deserve prompt assessment for inflammatory arthritis. Earlier treatment of confirmed disease can change its course. A positive blood test alone, however, is not a complete treatment plan. NICE guidance stresses that normal inflammation markers or negative antibodies should not delay referral when persistent synovitis is suspected, especially in small joints or more than one joint.

Bring your report, including the assay’s cutoff and units. Describe when symptoms began, how long they last, and which joints are affected. If a positive result was found incidentally and you have no symptoms, agree on which changes to watch for and when reassessment would be useful. Ordering ever larger blood panels is no substitute for that plan.

Frequently asked questions

What happens after a positive anti-CCP test?

The result is assessed alongside symptoms and a joint examination. Depending on the situation, further investigations may include inflammation markers, RF, or targeted imaging. Suspected inflammatory arthritis calls for timely rheumatology assessment.

Can anti-CCP be positive without RA?

Yes. Antibodies can precede the disease or occasionally occur without current RA. The frequency of positive results in healthy comparison groups is not the same as the proportion of healthy people among everyone who tests positive.

Does anti-CCP confirm the diagnosis?

It can provide strong support, but it does not replace clinical assessment. Actual joint inflammation, the pattern over time, and possible alternative explanations all matter. RA without detectable anti-CCP is also possible.

Why is my level so high?

The level may reflect your individual autoantibody profile and associated risk factors. It does not automatically mean your joints are severely inflamed right now. Symptoms and examination findings are central to judging current activity.

How quickly does anti-CCP change?

It often remains relatively stable. Antibodies may still be detectable even when treatment is working well. A level that does not fall is therefore not, on its own, evidence that treatment has failed.

Can smoking increase the risk?

Yes. Smoking is associated with seropositive RA, with risk also influenced by genetic susceptibility. In the cited Nurses’ Health Studies, current smoking was associated with a hazard ratio of 1.67 for seropositive RA compared with never smoking. Estimates differ with the population, exposure, and outcome; this is not a universal two- or threefold increase or a personal prediction. Quitting remains a useful step you can take.

What role does vitamin D play?

Vitamin D affects immune function, and low levels are often studied in RA. Correcting a deficiency is different from a proven treatment for the autoimmune response. It does not replace RA treatment or reliably eliminate antibodies.

Should anti-CCP be repeated regularly?

Repeated testing is usually of limited value for tracking disease activity. A targeted repeat may help clarify a borderline or unexpected result. Follow-up should focus mainly on clinical findings and appropriately selected measures of inflammation.

Sources

• Lee YH, Bae SC, Song GG (2015). Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis. Zeitschrift fur Rheumatologie, 74(10), 911-8. https://doi.org/10.1007/s00393-015-1598-x; Source

• Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004). Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis and rheumatism, 50(2), 380-6. https://doi.org/10.1002/art.20018; Source

• Navarro-Millán I, Darrah E, Westfall AO, Mikuls TR, Reynolds RJ, Danila MI, Curtis JR, CLEAR Investigators, Rosen A, Bridges SL (2016). Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans. Arthritis research & therapy, 18(1), 241. https://doi.org/10.1186/s13075-016-1126-7; Source

• Deane KD, Holers VM (2021). Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift. Arthritis & rheumatology (Hoboken, N.J.), 73(2), 181-193. https://doi.org/10.1002/art.41417; Source

• Massarenti L, Enevold C, Damgaard D, Ødum N, Garred P, Frisch M, Shelef MA, Jacobsen S, Nielsen CH (2021). PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. Frontiers in immunology, 12, 707690. https://doi.org/10.3389/fimmu.2021.707690; Source

• Perricone C, Ceccarelli F, Saccucci M, Di Carlo G, Bogdanos DP, Lucchetti R, Pilloni A, Valesini G, Polimeni A, Conti F (2019). Porphyromonas gingivalis and rheumatoid arthritis. Current opinion in rheumatology, 31(5), 517-524. https://doi.org/10.1097/BOR.0000000000000638; Source

• Lend K, Lampa J, Padyukov L, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Rudin A, Østergaard M, Haavardsholm EA, Hørslev-Petersen K, Uhlig T, Sokka-Isler T, Gudbjornsson B, Grondal G, Frazzei G, Christiaans J, Wolbink G, Rispens T, … van Vollenhoven RF (2024). Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial. Annals of the rheumatic diseases, 83(12), 1657-1665. https://doi.org/10.1136/ard-2024-226024; Source

• Gadeholt O, Hausotter K, Eberle H, Klink T, Pfeil A (2019). Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis. Clinical rheumatology, 38(9), 2403-2410. https://doi.org/10.1007/s10067-019-04602-5; Source

• Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, Collins G, Woolf AD, March L, Cross M (2019). Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Annals of the rheumatic diseases, 78(11), 1463-1471. https://doi.org/10.1136/annrheumdis-2019-215920; Source

• Zhao M, Mauer L, Sayles H, Cannon GW, Reimold A, Kerr GS, Baker JF, Thiele GM, England BR, Mikuls TR (2019). HLA-DRB1 Haplotypes, Shared Epitope, and Disease Outcomes in US Veterans with Rheumatoid Arthritis. The Journal of rheumatology, 46(7), 685-693. https://doi.org/10.3899/jrheum.180724; Source

• Liu X, Tedeschi SK, Barbhaiya M, Leatherwood CL, Speyer CB, Lu B, Costenbader KH, Karlson EW, Sparks JA (2019). Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses’ Health Studies. Arthritis care & research, 71(7), 914-924. https://doi.org/10.1002/acr.23837; Source

• Ahmadi P, Mahmoudi M, Kheder RK, Faraj TA, Mollazadeh S, Abdulabbas HS, Esmaeili SA (2023). Impacts of Porphyromonas gingivalis periodontitis on rheumatoid arthritis autoimmunity. International immunopharmacology, 118, 109936. https://doi.org/10.1016/j.intimp.2023.109936; Source

• Ostensen M, Villiger PM (2007). The remission of rheumatoid arthritis during pregnancy. Seminars in immunopathology, 29(2), 185-91. https://doi.org/10.1007/s00281-007-0072-5; Source

• Kesibi D, Rotondi M, Edgell H, Tamim H (2025). A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging. Seminars in arthritis and rheumatism, 73, 152747. https://doi.org/10.1016/j.semarthrit.2025.152747; Source

• Harbuz M (2002). Neuroendocrine function and chronic inflammatory stress. Experimental physiology, 87(5), 519-25. https://doi.org/10.1113/eph8702411; Source

• Karsh J, Keystone EC, Haraoui B, Thorne JC, Pope JE, Bykerk VP, Maksymowych WP, Zummer M, Bensen WG, Kraishi MM, Canadian Rheumatology Research Consortium (2011). Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. The Journal of rheumatology, 38(10), 2095-104. https://doi.org/10.3899/jrheum.110188; Source

• Makol A, Matteson EL, Warrington KJ (2015). Rheumatoid vasculitis: an update. Current opinion in rheumatology, 27(1), 63-70. https://doi.org/10.1097/BOR.0000000000000126; Source

• Harrison SR, Li D, Jeffery LE, Raza K, Hewison M (2020). Vitamin D, Autoimmune Disease and Rheumatoid Arthritis. Calcified tissue international, 106(1), 58-75. https://doi.org/10.1007/s00223-019-00577-2; Source

• Charoenngam N, Holick MF (2020). Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients, 12(7). https://doi.org/10.3390/nu12072097; Source

• Colebatch AN, Edwards CJ, Østergaard M, van der Heijde D, Balint PV, D’Agostino MA, Forslind K, Grassi W, Haavardsholm EA, Haugeberg G, Jurik AG, Landewé RB, Naredo E, O’Connor PJ, Ostendorf B, Potocki K, Schmidt WA, Smolen JS, Sokolovic S, … Conaghan PG (2013). EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Annals of the rheumatic diseases, 72(6), 804-14. https://doi.org/10.1136/annrheumdis-2012-203158; Source

• Mayo Clinic Laboratories. Cyclic Citrullinated Peptide Antibodies, IgG, Serum. https://www.mayocliniclabs.com/test-catalog/Overview/84182

• NICE. Rheumatoid arthritis in adults: management. Recommendations. https://www.nice.org.uk/guidance/ng100/chapter/Recommendations